191.82
+3.8(+2.02%)
Currency In USD
| Previous Close | 188.02 |
| Open | 187.28 |
| Day High | 192.44 |
| Day Low | 186.62 |
| 52-Week High | 202.41 |
| 52-Week Low | 110.04 |
| Volume | 1.22M |
| Average Volume | 1.78M |
| Market Cap | 28.15B |
| PE | 21.8 |
| EPS | 8.8 |
| Moving Average 50 Days | 181.47 |
| Moving Average 200 Days | 152.51 |
| Change | 3.8 |
If you invested $1000 in Biogen Inc. (BIIB) 10 years ago, it would be worth $700.94 as of March 02, 2026 at a share price of $191.82. Whereas If you bought $1000 worth of Biogen Inc. (BIIB) shares 5 years ago, it would be worth $710.84 as of March 02, 2026 at a share price of $191.82.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Biogen Announces Board Chair Transition
GlobeNewswire Inc.
Feb 11, 2026 10:00 PM GMT
Caroline Dorsa to retire from the Biogen Board of Directors; Dr. Maria C. Freire, Director since 2021, elected as new ChairCAMBRIDGE, Mass., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the Board of Directors ha
Biologics License Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Designated for Priority Review in China
GlobeNewswire Inc.
Feb 09, 2026 2:00 AM GMT
TOKYO and CAMBRIDGE, Mass., Feb. 08, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”
Nature Medicine Publishes Results from the Pivotal DEVOTE Study of High-Dose Regimen of Nusinersen in Spinal Muscular Atrophy
GlobeNewswire Inc.
Feb 04, 2026 12:30 PM GMT
Findings from DEVOTE support clinical benefits of the high-dose regimen of nusinersen (50 mg and 28 mg) in both treatment-naïve individuals and those previously treated with 12 mg nusinersenThe high-dose regimen of nusinersen also slowed neurodegener